MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer

Cathy A. Andorfer; Brian M. Necela; E. Aubrey Thompson; Edith A. Perez

doi:10.1016/j.molmed.2011.01.006

MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer

Cathy A. Andorfer, Brian M. Necela, E. Aubrey Thompson, Edith A. Perez

Research output: Contribution to journal › Review article › peer-review

150 Scopus citations

Abstract

Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

Original language	English (US)
Pages (from-to)	313-319
Number of pages	7
Journal	Trends in Molecular Medicine
Volume	17
Issue number	6
DOIs	https://doi.org/10.1016/j.molmed.2011.01.006
State	Published - Jun 2011

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology

Access to Document

10.1016/j.molmed.2011.01.006

Cite this

@article{ed670393e965427b85fbefd5698b20ad,

title = "MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer",

abstract = "Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.",

author = "Andorfer, {Cathy A.} and Necela, {Brian M.} and Thompson, {E. Aubrey} and Perez, {Edith A.}",

note = "Funding Information: The authors would like to acknowledge the Breast Cancer Research Foundation and the Donna Foundation for their financial support.",

year = "2011",

month = jun,

doi = "10.1016/j.molmed.2011.01.006",

language = "English (US)",

volume = "17",

pages = "313--319",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - MicroRNA signatures

T2 - Clinical biomarkers for the diagnosis and treatment of breast cancer

AU - Andorfer, Cathy A.

AU - Necela, Brian M.

AU - Thompson, E. Aubrey

AU - Perez, Edith A.

N1 - Funding Information: The authors would like to acknowledge the Breast Cancer Research Foundation and the Donna Foundation for their financial support.

PY - 2011/6

Y1 - 2011/6

N2 - Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

AB - Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

UR - http://www.scopus.com/inward/record.url?scp=79958767367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958767367&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2011.01.006

DO - 10.1016/j.molmed.2011.01.006

M3 - Review article

C2 - 21376668

AN - SCOPUS:79958767367

SN - 1471-4914

VL - 17

SP - 313

EP - 319

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 6

ER -

MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this